4-trifluoromethylbenzene boric acid | 274251-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-trifluoromethylbenzene boric acid
• 英文别名: p-trifluoromethylphenylboric acid；[4-(trifluoromethyl)phenoxy]boronic acid
• CAS: 274251-64-8
• 化学式: C₇H₆BF₃O₃
• 分子量: 205.929
• InChiKey: HCIMXTXCDVBLOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.05
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-trifluoromethylbenzene boric acid 、 1-(2-chloro-pyrimidin-5-yloxy)-2-(2,4-difluoro-phenyl)-3-(1H-1,2,4-triazole-1-yl)propan-2-ol 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 水 、 甲苯 为溶剂， 反应 5.0h， 以120 mg的产率得到1-(2-(4-trifluoromethylphenyl)pyrimidin-5-yloxy)-2-(2,4-difluoro-phenyl)-3-(1H-1,2,4-triazole-1-yl)propan-2-ol
  参考文献：
  名称：

  一种三氮唑醇芳杂环醚类衍生物及其制备方 法和应用

  摘要：

  本发明涉及一种三氮唑醇芳杂环醚类衍生物及其制备方法和应用，具体提供了所述的三氮唑醇芳杂环醚类衍生物的结构通式，制备方法，其晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药，以及用途。通过体外和体内抑菌实验证实本发明合成的化合物对人体致病真菌白色念珠菌、近平滑念珠菌、新生隐球菌、光滑假丝酵母菌、烟曲霉菌、石膏状小孢子菌、红色毛癣菌具有显著的抑制活性，优于氟康唑，而且该化合物还具有毒性低、抗真菌谱广等优点，因此可用于制备抗真菌药物。

  公开号：

  CN105237513B

文献信息

• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的羧酰胺化合物，其中A、B、W、X、Y、Z、R1、R2、R3和k的基团和残基具有权利要求1中所给出的含义。此外，本发明还涉及制备上述羧酰胺化合物的方法，以及含有本发明所述至少一种羧酰胺的制药组合物。基于它们的MCH受体拮抗活性，本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
  申请人：Maekawa Tsuyoshi

  公开号：US20060148858A1

  公开（公告）日：2006-07-06

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents —OR 4 (R 4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的化学式为(1)，其中环A是一个环，可以有1到3个取代基；环B是一个1,2-咪唑环，可以进一步具有1到3个取代基；Xa，Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个都是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个单环芳香环，可以进一步具有1到3个取代基；R代表-OR4（R4是氢原子或可选的取代烃基）等，或其盐或前药，可用作预防或治疗糖尿病等的药物。
• Halogenated benzene derivatives, and a liquid-crystalline medium
  申请人：Merck Patent Gesellschaft mit beschrankter Haftung

  公开号：US05308541A1

  公开（公告）日：1994-05-03

  The invention relates to novel halogenated benzene derivatives of the formula I ##STR1## in which n is 1 to 7 [sic], the rings A and B are each trans-1,4-cyclohexylene, or one of the rings A and B is alternatively 1,4-phenylene or 3-fluoro-1,4-phenylene, X is F, Cl, --CHF.sub.2, --CF.sub.3, --CN, --OCF.sub.3 or --OCHF.sub.2, Y and Z are each, independently of one another, H or F, r=1 or, in the case where s=1, B=trans-1,4-cyclohexylene and simultaneously X=CHF.sub.2, --CF.sub.3, --OCF.sub.3 or --OCHF.sub.2, r is alternatively 0, and s=1 or, in the case where B=1,4-phenylene or 3-fluoro-1,4-phenylene, s=0.

  本发明涉及公式I的新型卤代苯衍生物，其中n为1至7，环A和环B分别为反式1,4-环己烯基，或环A和环B中的一个交替为1,4-苯基或3-氟-1,4-苯基，X为F、Cl、--CHF.sub.2、--CF.sub.3、--CN、--OCF.sub.3或--OCHF.sub.2，Y和Z各自独立地为H或F，r=1或在s=1的情况下，B=反式1,4-环己烯基且同时X=CHF.sub.2、--CF.sub.3、--OCF.sub.3或--OCHF.sub.2，r也可以是0，s=1或在B=1,4-苯基或3-氟-1,4-苯基的情况下，s=0。
• Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof
  申请人：Tozawa Takashi

  公开号：US20080167307A1

  公开（公告）日：2008-07-10

  According to the present invention, a compound represented by the following formula (I) having a superior PPAR α agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.

  根据本发明，可以提供一种具有卓越的PPARα激动剂作用并同时显示降脂作用的化合物，该化合物表示为以下公式（I），并且还可以提供一种用作该化合物的合成中间体的化合物。
• Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors
  申请人：Amberg Wilhelm

  公开号：US20100184787A1

  公开（公告）日：2010-07-22

  The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders.

  本发明涉及通式（I）的杂环取代的胍化合物、其对映体、二对映异构体和/或互变异构体，以及其药学上可接受的盐和已知化合物的前药。本发明还涉及将所述杂环取代的胍化合物用作5-HT5受体的结合伙伴，用于治疗和/或预防由5-HT5受体活性调节的疾病，特别是用于治疗和/或预防神经退行性和神经精神障碍，以及与该类障碍相关的症状和功能障碍。